Atrium Therapeutics, Inc. (RNA) Financial Statements
Atrium Therapeutics, Inc. (RNA) reported trailing twelve-month revenue of $3.0M (down 94.3% year on year) and net income of -$20.2M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · read by EquiReason
RNAAtrium Therapeutics, Inc.Follow RNA — free
—
Price chart with a free account
- Market cap
- 140.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Loading the filed annual statements…
USD millions · SEC XBRL
Atrium Therapeutics, Inc. — questions
- What is Atrium Therapeutics, Inc.'s revenue?
- $3.0M over the twelve months to the latest filing, down 94.3% year on year, from its 10-Q and 10-K filings.
- What is Atrium Therapeutics, Inc.'s net income?
- -$20.2M over the twelve months to .
Every figure on this page comes from Atrium Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.